NCT00416312 · ADVERSE EVENTS

Adverse events

Iodine I 131 Tositumomab or Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma · Source last updated 2018-08-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame: Not reported
Other-event reporting threshold: 0%

Adverse event data was not collected since this was a data collection study tacked on to routine patient treatment

Participants affected / participants at risk, as reported
Safety group	Serious events	Other events	Deaths
Conventional & Patient-specific Dosimetry Tumor absorbed dose calculations determined using both conventional dosimetry and 3D-RD patient-specific dosimetry software.	0 / 0	0 / 0	0 / 0

Group identifiers: EG000: Conventional & Patient-specific Dosimetry

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Complete source fields

description

Adverse event data was not collected since this was a data collection study tacked on to routine patient treatment

event Groups

deaths Num Affected
0
deaths Num At Risk
0
description
Tumor absorbed dose calculations determined using both conventional dosimetry and 3D-RD patient-specific dosimetry software.
id
EG000
other Num Affected
0
other Num At Risk
0
serious Num Affected
0
serious Num At Risk
0
title
Conventional & Patient-specific Dosimetry

frequency Threshold

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice